- /
- Supported exchanges
- / US
- / ARWR.NASDAQ
Arrowhead Pharmaceuticals Inc (ARWR NASDAQ) stock market data APIs
Arrowhead Pharmaceuticals Inc Financial Data Overview
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, an investigational RNAi therapeutic in Phase 1 clinical trials. The company also develops ARO-INHBE, to reduce the hepatic expression of the INHBE gene and its secreted gene product, Activin E in Phase 1/2a clinical trials; ARO-ALK7 to silence adipocyte expression of the ACVR1C gene in Phase 1/2a clinical trials; ARO-RAGE to reduce production of the receptor for advanced glycation end products in Phase 1/2a clinical trials; and ARO-MAPT, an investigational RNAi-based therapy. In addition, it is developing ARO-C3 to reduce production of C3 in Phase 1/2a clinical trials; and ARO-CFB to reduce hepatic expression of CFB in a Phase 1/2a clinical trials. The company has collaboration and license Agreements with Glaxosmithkline Intellectual Property (No. 3) Limited; Takeda Pharmaceutical Company Limited; Amgen Inc.; Novartis Pharma AG; Madrigal Pharmaceuticals, Inc.; and Sarepta Therapeutics, Inc. Arrowhead Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Pasadena, California.
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Arrowhead Pharmaceuticals Inc (top by weight)
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Arrowhead Pharmaceuticals Inc data using free add-ons & libraries
Get Arrowhead Pharmaceuticals Inc Fundamental Data
Arrowhead Pharmaceuticals Inc Fundamental data includes:
- Net Revenue: 451 M
- EBITDA: -680 548 992
- Earnings Per Share: -5
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
Get Arrowhead Pharmaceuticals Inc Earnings data
Corporate Events Calendar & News package for
What’s included:
- Latest Release: 2026-11-12
- EPS/Forecast: -1.59
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Arrowhead Pharmaceuticals Inc News
New
ARWR: Commercial Momentum Builds Ahead of Potential Expansion into sHTG Market
By David Bautz, PhD NASDAQ: ARWR READ THE FULL ARWR RESEARCH REPORT Business Update Update on REDEMPLO Launch Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) reported encouraging progress with the...
Could RNAi Trial Data Alter The Investment Case For Arrowhead Pharmaceuticals (ARWR)?
Arrowhead Pharmaceuticals reported full year 2026 revenue of US$450.82 million, down sharply from US$829.45 million, alongside a widened net loss of US$724.21 million and new cardiometabolic RNAi data...
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
PASADENA, Calif., November 17, 2026--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that as an inducement to entering into employment with the Company, on October 22, ...
Chardan revisits a top pick in biotech following fiscal 2026 results
Investing.com -- Chardan analyst Keay Nakae examined recent developments at Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR), one of the firm's top picks for 2026, following the company's fiscal year 2026 ...
Corporate Events Calendar & News package for
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.